Physician profile
Albert Daniel Abrams
NPI 1568454833
$6,846.99
in general payments reported to CMS, 2019-2025
23 companies · $57.75 in 2025
The $57.75 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,823 · 2020: $1,461 · 2021: $1,277 · 2022: $1,178 · 2023: $13.92 · 2024: $36.76 · 2025: $57.75.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $108.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $108.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,617.12 | 2019-2022 | |
| Abbvie INC. | $997.98 | 2019-2025 | Rinvoq |
| Janssen Biotech, INC. | $782.55 | 2019-2022 | |
| Pfizer INC. | $630.04 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $542.66 | 2019-2022 | |
| Ucb, INC. | $534.40 | 2019-2025 | Bimzelx, Cimzia |
| Glaxosmithkline, LLC. | $430.18 | 2019-2024 | Benlysta |
| Lilly USA, LLC | $178.02 | 2019-2022 | |
| Genentech USA, INC. | $174.37 | 2019-2020 | |
| Mallinckrodt Hospital Products INC. | $148.05 | 2020-2022 | |
| Horizon Therapeutics Plc | $146.62 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $107.72 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $88.67 | 2019-2020 | |
| Aurinia Pharma U.S., INC. | $78.18 | 2021-2022 | |
| Sobi, INC | $72.00 | 2020-2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $69.37 | 2019 | |
| Genzyme Corporation | $61.18 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $61.12 | 2021-2022 | |
| Mallinckrodt Enterprises LLC | $53.23 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $20.21 | 2021 | |
| Radius Health, INC. | $20.10 | 2021 | |
| Actelion Pharmaceuticals US, INC. | $16.88 | 2021 | |
| Pacira Therapeutics, INC. | $16.34 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Albert Abrams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.